Detail akcie Cingulate Rg online

Business Summary: Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cingulate Inc revenues was not reported. Net loss increased 55% to $15.9M. Higher net loss reflects Research and development increase of 52% to $7.8M (expense), General and administrative increase of 52% to $6.6M (expense), Interest and other income (expense), net decrease from $23K (income) to $235K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$15.02 to -$3.49.